Compare FOXF & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | IRWD |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.2M | 520.6M |
| IPO Year | N/A | 2010 |
| Metric | FOXF | IRWD |
|---|---|---|
| Price | $19.10 | $5.21 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $30.67 | $5.74 |
| AVG Volume (30 Days) | 570.9K | ★ 7.4M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | ★ $1,459,086,000.00 | $338,987,000.00 |
| Revenue This Year | $6.82 | N/A |
| Revenue Next Year | $3.63 | $37.22 |
| P/E Ratio | ★ N/A | $30.44 |
| Revenue Growth | ★ 6.22 | N/A |
| 52 Week Low | $13.08 | $0.53 |
| 52 Week High | $31.18 | $5.78 |
| Indicator | FOXF | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 71.70 |
| Support Level | $18.90 | $4.17 |
| Resistance Level | $19.94 | $5.57 |
| Average True Range (ATR) | 0.71 | 0.39 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 69.32 | 80.40 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.